DEA is investigating two pharmacies in Colorado. It doesn’t want those pharmacies to know it is investigating them. But it needs information relating to these pharmacies and the prescriptions they are dispensing to assist with its investigation. So DEA is
DEA Chronicles
Controlled Substance Litigation & Compliance Issues
DEA Chronicles, published by Cote Law PLLC, focuses on legal and regulatory issues related to the Controlled Substances Act and Drug Enforcement Administration (DEA) compliance. The blog covers topics such as controlled substance litigation, DEA enforcement actions, suspicious order monitoring, due diligence obligations, drug policy, legislation affecting controlled substances, and state law interactions. It also addresses challenges faced by distributors, pharmacies, and manufacturers in maintaining compliance, including the impact of new regulations and enforcement trends. The blog provides updates on DEA guidance, compliance software solutions, and legislative developments relevant to controlled substance regulation and enforcement.
Latest from DEA Chronicles - Page 5
Judge Dissolves ISO Against West Virginia Pharmacy: Suspicion Of Diversion Not Enough to Support Suspension
In a decision issued on October 30, Judge Joseph Goodwin of the Southern District of West Virginia dissolved an Order of Immediate Suspension of Registration (“ISO”) issued by DEA against Oak Hill Hometown Pharmacy, a West Virginia pharmacy. Without getting…
DEA Announces its New Suspicious Orders Report System Online: the devil is in the details we don’t yet have
On October 23, 2019, the Drug Enforcement Administration (DEA) announced the launch of its Suspicious Orders Report System (SORS) Online, a portal allowing for the centralized reporting of suspicious orders, as required by the SUPPORT ACT.
According to DEA’s…
What’s new in pharmacy law? Join me at the 2019 ASPL Fall Meeting and find out!
If you are looking to stay informed on legal issues as they pertain to pharmacy, pharmaceuticals and related products and services, there’s still time to register for the American Society for Pharmacy Law Fall Meeting. You’ll learn from industry experts…
Problems Identified, Solutions Proposed: the OIG Review of DEA
Is “Suspicious Order” about to be defined?
The recently-released DOJ OIG Review of the Drug Enforcement Administration’s Regulatory and Enforcement Efforts to Control the Diversion of Opioids has met with extensive media coverage focused on the sexier aspects of the…
FDA Approves New Packaging for “Poor Man’s Methadone”
While acknowledging the safety of the approved daily doses of OTC loperamide for adults (8mg per day) and prescription loperamide (16mg per day), the FDA recently approved new package-size and package-type limits for the brand-name OTC tablet and capsule forms…
DEA Proposes Decreasing Opioid Quotas for 2020
Quota Reductions
DEA is out with its proposed 2020 aggregate production quotas for Schedule I and II controlled substances, and they have been reduced dramatically from 2019’s numbers. From the press release:
DEA proposes to reduce the amount of…
DEA Decisions: Registrations Not Automatically Revoked by Medicare/Medicaid Exclusions
Jeffrey Stein, M.D.; Decision and Order
Uttam Dhillon, DEA Acting Administrator, issued a final order today in the case of the revocation of a New York doctor’s DEA registration. But its implications go well beyond this doctor’s circumstances.
The Facts…
DEA and the Surgeon General Issue Statements Regarding Marijuana
Last week was an active week when it comes to marijuana policy. The Drug Enforcement Administration (DEA) announced that it will begin considering (and approving?) applications to allow for the manufacture (growing) of marijuana for research purposes. Shortly thereafter, United…
Be Part of the Solution to the Opioid Crisis – Make the Pledge!
Just as there are several factors that contributed to the opioid epidemic, there are a myriad of solutions that, in tandem, will make a difference in the lives of those impacted by opioid abuse and may prevent others from misusing and…